PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer

Related Experiment Video

Updated: May 30, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Emmanuel O Johnson1, Kuei-Hua Chang, Yolanda de Pablo

  • 1Department of Chemistry and Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.

Journal of Cell Science
|August 3, 2011
PubMed

Insights

Pleckstrin-homology-like domain protein PHLDA1 is degraded by Aurora A kinase in breast cancer. PHLDA1 upregulation counteracts Aurora A

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aurora A kinase is frequently overexpressed in breast carcinomas, contributing to malignancy.
  • Pleckstrin-homology-like domain protein PHLDA1 is identified as a key regulator in breast cancer progression.

Purpose of the Study:

  • To investigate the role of PHLDA1 as a substrate of Aurora A kinase.
  • To elucidate the feedback loop between Aurora A and PHLDA1 in breast carcinoma.
  • To explore PHLDA1 as a therapeutic target in breast cancer.

Main Methods:

  • Chemical genetic approach to identify Aurora A kinase targets.
  • Analysis of PHLDA1 expression and its correlation with prognosis and estrogen receptor status.
  • In vitro studies to demonstrate Aurora A-mediated phosphorylation and degradation of PHLDA1.
  • Investigation of the feedback mechanism between PHLDA1 and Aurora A.

Main Results:

  • PHLDA1 is a direct substrate of Aurora A kinase, and its phosphorylation leads to degradation.
  • PHLDA1 downregulation is a significant prognostic predictor in breast carcinoma and correlates with ER expression.
  • PHLDA1 negatively regulates Aurora A, establishing a feedback loop that antagonizes oncogenic pathways.
  • PHLDA1 upregulation synergizes with Aurora A inhibition to promote cancer cell death.

Conclusions:

  • PHLDA1 degradation by Aurora A is a critical mechanism promoting breast cancer malignancy.
  • PHLDA1 upregulation represents a potential therapeutic strategy for modulating Aurora A deregulation.
  • A novel chemical genetic approach targeting Aurora A mutations was developed, applicable to other kinases.

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...